Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
暂无分享,去创建一个
B. Quesnel | C. Berthon | O. Nibourel | Laure Goursaud | M. Wémeau | P. Chauvet | P. Lionne-Huyghe | B. Carpentier
[1] P. Campbell,et al. Life histories of myeloproliferative neoplasms inferred from phylogenies , 2022, Nature.
[2] R. Levine,et al. A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN. , 2020, Blood advances.
[3] O. Odenike,et al. Genomics of MPN progression. , 2020, Hematology. American Society of Hematology. Education Program.
[4] V. Ugo,et al. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. , 2020, Blood advances.
[5] V. Najfeld,et al. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms , 2020, Acta Haematologica.
[6] M. Voso,et al. Treatment of Philadelphia‐negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors , 2019, Hematological oncology.
[7] U. Gianelli,et al. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options , 2019, International journal of molecular sciences.
[8] M. Giovannini,et al. Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm , 2018, Acta Haematologica.
[9] R. Hoffman,et al. Outcomes and predictors of survival in blast phase myeloproliferative neoplasms. , 2018, Leukemia research.
[10] A. Bagg,et al. JAK2 V617F‐positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group , 2018, British journal of haematology.
[11] S. Langabeer,et al. Protracted Clonal Trajectory of a JAK2 V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia , 2018, Case reports in hematology.
[12] R. Houot,et al. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase , 2018, Leukemia & lymphoma.
[13] D. Birnbaum,et al. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms , 2018, American journal of hematology.
[14] A. Tefferi,et al. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. , 2018, Blood advances.
[15] P. Guglielmelli,et al. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts , 2018, Leukemia.
[16] M. Giovannini,et al. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation , 2017, Acta oncologica.
[17] C. Récher,et al. Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia , 2017, Oncotarget.
[18] E. Raffoux,et al. Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone , 2017, Leukemia & lymphoma.
[19] H. Kantarjian,et al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. , 2015, Leukemia research.
[20] M. Voso,et al. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. , 2015, Leukemia research.
[21] V. Bhatt. Leukemic transformation in essential thrombocythemia. , 2014, Future oncology.
[22] S. Armstrong,et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms , 2014, Proceedings of the National Academy of Sciences.
[23] M. Minden,et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. , 2013, Blood.
[24] B. Quesnel,et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). , 2010, Blood.
[25] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[26] P. Guglielmelli,et al. Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. , 2007, Blood.
[27] H. Byun,et al. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition , 2007, British journal of haematology.